2. Search Result
Search Result
Results for "

glucagon receptor antagonist

" in MedChemExpress (MCE) Product Catalog:

28

Inhibitors & Agonists

11

Peptides

1

Inhibitory Antibodies

1

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-50159
    Glucagon receptor antagonists-3

    		GCGR Metabolic Disease
    Glucagon receptor antagonists-3 is a highly potent glucagon receptor antagonist.
    Glucagon receptor antagonists-3
  • HY-50158
    Glucagon receptor antagonists-2

    		GCGR Metabolic Disease
    Glucagon receptor antagonists-2 is a highly potent glucagon receptor antagonist.
    Glucagon receptor antagonists-2
  • HY-10036
    Glucagon receptor antagonists-1

    		GCGR Metabolic Disease
    Glucagon receptor antagonists-1 is a highly potent glucagon receptor antagonist.
    Glucagon receptor antagonists-1
  • HY-19947
    PF-06291874
    1 Publications Verification

    glucagon receptor antagonists-4

    		 GCGR Metabolic Disease
    PF-06291874 is a highly potent, non-peptide and orally active glucagon receptor antagonist. PF-06291874 is under the study for type 2 diabetes mellitus (T2DM) .
    PF-06291874
  • HY-148844
    GCGR antagonist 2

    		GCGR Metabolic Disease
    GCGR antagonist 2, a Furan-2-carbohydrazide, is an orally active glucagon receptor antagonist. GCGR antagonist 2 binds to hGluR with an Kd value of 2.3 nM, and inhibits rat receptor with an IC50 value of 0.43 nM. GCGR antagonist 2 inhibits glucagon-stimulated glycogenolysis .
    GCGR antagonist 2
  • HY-50663
    MK 0893
    5 Publications Verification

    		 GCGR Metabolic Disease
    MK 0893 is a potent and selective glucagon receptor antagonist with an IC50 of 6.6 nM.
    MK 0893
  • HY-128781
    Glucagon receptor antagonists-5

    		GCGR Metabolic Disease
    Glucagon receptor antagonists-5 (compound 13K) is a potent and orally bioavailable indazole-based glucagon receptor antagonist (Ki=32 nM). Glucagon receptor antagonists-5 has potential for the treatment of type 2 diabetes mellitus (T2DM) .
    Glucagon receptor antagonists-5
  • HY-119739
    Skyrin

    		GCGR Metabolic Disease Cancer
    Skyrin is an anthraquinone compound that can be isolated from almond fruit. Skyrin is a receptor-selective glucagon antagonist. Skyrin can inhibit the growth of tumor cells .
    Skyrin
  • HY-19374
    BAY-27-9955

    		GCGR Metabolic Disease
    BAY-27-9955 is an orally active non-peptide glucagon receptor antagonist. Bay 27-9955 competitively blocks the interaction of glucagon with the human glucagonreceptor at an IC50 value of 110 nM. BAY-27-9955 can be used for the study of type 2 diabetes .
    BAY-27-9955
  • HY-P1143
    [Des-His1,Glu9]-Glucagon amide

    		GCGR Metabolic Disease
    [Des-His1,Glu9]-Glucagon amide is a potent and peptide antagonist of the glucagon receptor, with a pA2 of 7.2. [Des-His1,Glu9]-Glucagon amide is potentially useful in the study of the pathogenesis of diabetes .
    [Des-His1,Glu9]-Glucagon amide
  • HY-P1143A
    [Des-His1,Glu9]-Glucagon amide TFA

    		GCGR Metabolic Disease
    [Des-His1,Glu9]-Glucagon amide TFA is a potent and peptide antagonist of the glucagon receptor, with a pA2 of 7.2. [Des-His1,Glu9]-Glucagon amide TFA is potentially useful in the study of the pathogenesis of diabetes .
    [Des-His1,Glu9]-Glucagon amide TFA
  • HY-103547
    L-168049

    		GCGR Metabolic Disease
    L-168049 is a potent, selective, orally active and non-competitive glucagon receptor antagonist with IC50s of 3.7 nM, 63 nM, and 60 nM for human, murine, and canine glucagon receptors, respectively .
    L-168049
  • HY-12735
    SCH 900822

    		GCGR Metabolic Disease Endocrinology
    SCH 900822 is a potent and selective glucagon receptor (hGCGR) antagonist that blocks the binding of glucagon to its receptor, thereby reducing hepatic glycogenolysis and gluconeogenesis, thereby lowering blood glucose production. SCH 900822 can be used in the study of type 2 diabetes .
    SCH 900822
  • HY-P3608
    [Des-His1,Glu9] Glucagon

    		GCGR Metabolic Disease
    [Des-His1,Glu9] Glucagon is a potent glucagon receptor system peptide antagonist. [Des-His1,Glu9] Glucagon enhances the glucose-stimulated release of insulin from pancreatic islet cells. [Des-His1,Glu9] Glucagon can be used to research diabetes .
    [Des-His1,Glu9] Glucagon
  • HY-12525
    LGD-6972

    		GCGR Metabolic Disease
    LGD-6972 is a selective and orally active glucagon receptor antagonist. LGD-6972 has the potential for type 2 diabetes research .
    LGD-6972
  • HY-12525A
    LGD-6972 sodium

    		GCGR Metabolic Disease
    LGD-6972 sodium is a selective and orally active glucagon receptor antagonist. LGD-6972 sodium has the potential for type 2 diabetes research .
    LGD-6972 sodium
  • HY-P99383
    Volagidemab

    REMD-477; AMG-477

    		 GCGR Metabolic Disease
    Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D) .
    Volagidemab
  • HY-19904
    Adomeglivant
    4 Publications Verification

    LY2409021

    		 GCGR Metabolic Disease
    Adomeglivant (LY2409021) is a potent, selective glucagon receptor (GluR) allosteric antagonist. Adomeglivant is widely used in the research for type 2 diabetes mellitus .
    Adomeglivant
  • HY-101116
    GLP-1R Antagonist 1
    2 Publications Verification

    		 GCGR Metabolic Disease
    GLP-1R Antagonist 1 (compound 5d) is an orally active, CNS penetrant and non-competitive antagonist of glucagon-like peptide 1 receptor (GLP-1R), with an IC50 of 650 nM .
    GLP-1R Antagonist 1
  • HY-P2497
    Exendin (5-39)
    1 Publications Verification

    		 GCGR Neurological Disease
    Exendin (5-39) is a potent glucagon-like peptide 1 (GLP-1) receptor antagonist. Exendin (5-39) improves memory impairment in β-amyloid protein-treated rats .
    Exendin (5-39)
  • HY-107129
    MK-3577

    		GCGR Metabolic Disease
    MK-3577 is an orally effective glucagon receptor (GCGR) antagonist that reduces hepatic glucose production and lowers blood glucose levels by blocking glucagon receptors on target organs, primarily the liver. Pharmacokinetic analysis in domestic cats indicates that MK-3577 reaches peak levels 3 to 4 hours after oral administration, with a half-life of approximately 15 hours. MK-3577 can be used in diabetes research .
    MK-3577
  • HY-116930
    S-20928

    		Melatonin Receptor Metabolic Disease
    S-20928 is an antagonist for melatonin receptor through inhibition of binding of melatonin to its receptors. S-20928 enhances the 2-Deoxy-D-glucose (2DG) (HY-13966)-induced increase in blood glucose and glucagon levels in rats brain .
    S-20928
  • HY-116854
    NNC 92-1687

    		GCGR Metabolic Disease
    NNC 92-1687 is a non-peptide competitive human glucagon receptor antagonist (IC50=20 μM; Ki=9.1 μM). NNC 92-1687 can be used in the research of type 2 diabetes .
    NNC 92-1687
  • HY-106103
    Seglitide

    MK-678; L-363586

    		 Somatostatin Receptor Neurological Disease Metabolic Disease
    Seglitide (MK-678) is a potent, orally active somatostatin receptor 2 (SSTR2) agonist, and also a competitive antagonist of SSTR14, SSTR25, and SSTR28. Seglitide has antihypertensive effects and can inhibit plasma glucagon and growth hormone. Seglitide can be used for research on diabetes .
    Seglitide
  • HY-106103A
    Seglitide acetate

    MK 678 acetate; L 36358 acetate

    		 Somatostatin Receptor Neurological Disease Metabolic Disease
    Seglitide acetate (MK 678; L 36358 acetate) is a potent, orally active somatostatin receptor 2 (SSTR2) agonist, and also a competitive antagonist of SSTR14, SSTR25, and SSTR28. Seglitide acetate has antihypertensive effects and can inhibit plasma glucagon and growth hormone. Seglitide acetate can be used for research on diabetes .
    Seglitide acetate
  • HY-P1141
    GLP-1(9-36)amide

    		GCGR Metabolic Disease
    GLP-1(9-36)amide is a major metabolite of glucagon-like peptide-1-(7-36) amide formed by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1(9-36)amide acts as an antagonist to the human pancreatic GLP-1 receptor .
    GLP-1(9-36)amide
  • HY-P1141A
    GLP-1(9-36)amide TFA

    		GCGR Metabolic Disease
    GLP-1(9-36)amide TFA is a major metabolite of glucagon-like peptide-1-(7-36) amide formed by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1(9-36)amide TFA acts as an antagonist to the human pancreatic GLP-1 receptor .
    GLP-1(9-36)amide TFA
  • HY-P3542
    Des His1, Glu8 Exendin-4

    		GCGR Metabolic Disease
    Des His1, Glu8 Exendin-4 is a potent glucagon-like peptide-1 receptor (GLP-1-R) antagonist. Des His1, Glu8 Exendin-4 improves glucose homeostasis by regulating both insulin secretion and glucose production. Des His1, Glu8 Exendin-4 can be used for the research of type 2 diabetic and gastrointestinal .
    Des His1, Glu8 Exendin-4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: